Allogran-R®

A highly consistent, polycrystalline and porous calcium phosphate bone substitute that provides an osteoconductive scaffold for use in trauma and spine.

Synthetic bone substitute

Allogran-R is a fully absorbable β tri-calcium phosphate. Its irregular particles, when combined with saline or blood, assume a cohesive regenerative matrix for the treatment of trauma, spine and non-unions:

  • Engineered porosity for complete absorption in 6–12 months
  • Osteoconductive
  • No risk of disease transmission
  • Elimination of donor site morbidity

 

Absorption process in vivo

STAGE 1 Physiochemical dissolution of individual particles
STAGE 2 Biological absorption by osteoclasts

Microporous structure

Electron micrograph showing microporous structure of Allogran-R granules.

electron-microscope[1].jpg

For indications, contraindications, warnings and precautions see Instructions for Use.

©2017, Biocomposites and Allogran are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or re-publication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

 

Engineered for absorption

Biocomposites, through its proprietary process, has engineered a multiporous granular matrix with outstanding biocompatibility, which is truly absorbable through the process of dissolution and cell mediation.

Bio-replaceable implant scaffold Inter-granular macroporosity > 100 µm (vascularisation)
Osteoconductive Polycrystalline microporosity < 10 µm for early cell attachment
Bioactive Osteoconductive matrix promoting osteoblast proliferation
Biocompatible High purity β tri-calcium phosphate with controlled chemistry
Total resorption (absorption) Stoichiometric calcium to phosphorus ratio 1.5

Osteoblast proliferation

Micrograph showing osteoblasts proliferating on the micro-porous surface of Allogran-R at 21 days in vitro.

proliferation.png

 

Absorption of Allogran-R1

absorption-allogran-new.png

a) Supracondylar fracture of the left femur 66-year-old female
b) 3 months post-operatively after fracture plated and packed with Allogran-R
c) 6 months post-operatively
d) 10 months post-operatively, radiographic evidence of new bone with advanced absorption of Allogran-R

Reference: 1. Use of Allogran-R in the treatment of a supracondylar fracture of the left femur. Courtesy of Mr M A Bawarish, Darlington Memorial Hospital, Darlington, Co. Durham, UK

For indications, contraindications, warnings and precautions see Instructions for Use.

©2017, Biocomposites and Allogran are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or re-publication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

 

 

Technical profile

Appearance
Irregular granules combine to form a multiporous matrix.

  • Average particle size of 2.0 mm

Indications
To fill a bone defect caused by:

  • Delayed union or non-union
  • Removal of tumour or cyst
  • Trauma
  • Osteomyelitis

Specifications

CHARACTERISTICSSPECIFICATION
Chemical Ca3(PO4)2 (Conforms to ASTM F1088-04a)
Physical Irregular granule ~ 2000 µm
Purity >99%
Crystallinity >95% β tri-calcium phosphate
Matrix structure >200 µm macropores, < 10 µm micropores

Flexible options

 POT SIZEORDER CODES
Allogran-R

Supplied sterile, ready
for immediate use
5 cc 800–005
10 cc 800–010

 

For indications, contraindications, warnings and precautions see Instructions for Use.

©2017, Biocomposites and Allogran are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or re-publication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

 

 

Transform outcomes

 

to-all-cs1.pngUse of Allogran-R in the treatment of intra-articular calcaneal fracture

Patient presented with: subtalar degenerative disease in the right foot, following an intra-articular calcaneal fracture.

Outcome: At 3 months post-operatively, the patient reported a reduction in pain. Radiographic examination indicated integration of the graft material with new bone formation at the fusion site. At 9 months post-operatively, the patient reported uneventful healing. Further radiographic examination indicated significant absorption of the graft material and effective radiographic fusion at the site.

Click to read full case study

 

to-all-cs2.pngUse of Allogran-R in the treatment of a supracondylar fracture of the left femur

Patient presented with: a supracondylar fracture of the left femur. 

Outcome: At 3 months post-operatively, the fracture site was stable and the Allogran-R granules were evident. At 10 months post-operatively, there was radiographic evidence of new bone at the site with advanced absorption of the bone graft material.

Click to read full case study

 

For indications, contraindications, warnings and precautions see Instructions for Use.

©2017, Biocomposites and Allogran are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or re-publication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

 

 

Trauma

Bone and joint trauma, such as fractures and dislocations, are common and vary in severity from single fractures to multiple, life-threatening musculoskeletal injuries.

Spine

The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

Case studies

Read case studies for trauma

Case studies

Read case studies for spine

Find out more